1.
NEJM Evid
; 2(2): EVIDoa2200293, 2023 Feb.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38320033
RESUMEN
Anticoagulation in Non-Critically Ill Covid-19 PatientsMcQuilten et al. conducted a randomized clinical trial comparing low-dose, intermediate-dose, low-dose plus aspirin, and therapeutic-dose anticoagulation in patients with Covid-19 of diverse ethnicities in high-, low-, and middle-income countries.
Asunto(s)
COVID-19 , Humanos , Anticoagulantes/farmacología , Coagulación Sanguínea , Aspirina/farmacología
2.
NEJM Evid
; 2(11): EVIDoa2300132, 2023 Nov.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38320527
RESUMEN
A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.